Norwegian Medicines Agency

What Norwegian Medicines Agency does

The Norwegian Medicines Agency, officially Direktoratet for medisinske produkter (DMP), is Norway's national regulatory authority for medicines, medical devices, blood/cells/tissues, and veterinary pharmaceuticals. Operating under the Norwegian Ministry of Health and Care Services and headquartered in Oslo, the agency was founded in 1974 and employs between 251 and 500 staff. Its portfolio spans marketing authorization approvals, clinical trial authorizations, pharmacovigilance and adverse reaction monitoring, medical device conformity assessment, health technology assessments (Metodevurdering), national supply security and shortage management, pharmacy licensing, veterinary medicine regulation, and blood/cells/tissue oversight. DMP implements EU regulations (CTIS, Eudamed, SoHO) at the national level and participates in EU-wide procedures including MRP, DCP, and the Centralized Procedure, as well as the FAST-EU pilot for multinational clinical trials.

DMP's technology stack comprises internal regulatory databases and digital systems rather than commercial products. Key systems include Legemiddelsøk (public drug search), Legemiddelgrunndata (drug registry data), a drug interaction database, and FHIR-based healthcare data exchange services. The agency does not disclose proprietary technology, APIs, or AI/ML capabilities. Its communications are delivered through the dmp.no portal, Facebook, LinkedIn, email newsletters, and press releases. Leadership includes medical director Steinar Madsen; broader management team details are not disclosed in the input data.

As a government directorate, DMP does not operate a commercial revenue model. Its operations are funded through Norwegian state budgets and regulatory fees for services such as marketing authorization applications, clinical trial approvals, and inspections. The agency holds exclusive statutory jurisdiction over its regulatory functions, eliminating direct competitive pressure. Recent strategic positioning has emphasized mandate expansion from pharmaceuticals into medical devices and SoHO substances, alongside digital modernization aligned with EU regulatory frameworks.

Name

Norwegian Medicines Agency

Legal name

Direktoratet for medisinske produkter

Website

https://legemiddelverket.no

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

251–500 employees

Short description

The Norwegian Medicines Agency (Direktoratet for medisinske produkter, DMP) is Norway's national regulatory authority overseeing marketing authorizations, pharmacovigilance, medical device conformity, health technology assessments, and supply security for medicines, serving pharmaceutical companies, device manufacturers, pharmacies, and healthcare institutions across Norway.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulatory Services

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615)

akta.pro industry

PRIMARYHLAJADAA

Drug Regulators (Human Pharmaceuticals)

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAJADAC

Medical Device Regulators

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAJADAF

Clinical Trials Authorization & Oversight (GCP)

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAJACAI

Controlled Substances & Pharmacy Regulation Authorities

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities

SECONDARYHLAJACAD

Healthcare Quality & Patient Safety Regulators

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities

Keywords

• Pharmaceutical regulation
• Medical device oversight
• Marketing authorisation
• Pharmacovigilance services
• Clinical trial assessment

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Distribution channels1 record

Marketing channels4 records

Core offering

The Norwegian Medicines Agency is the national regulatory authority responsible for approving and supervising medicines, medical devices, and products derived from blood, cells, and tissues in Norway. It evaluates marketing authorisation applications, monitors medicine safety through pharmacovigilance, assesses clinical trials, and provides regulatory guidance to pharmaceutical companies, healthcare professionals, and the public.

Product overview

Norwegian Medicines Agency (Direktoratet for medisinske produkter, DMP) is a government regulatory agency, not a commercial product company. It provides a portfolio of regulatory and public health services including drug approval and monitoring, adverse reaction reporting, medical device oversight, health technology assessments for public reimbursement, supply security management, drug interaction databases, pharmacy licensing, and veterinary medicine regulation. The agency operates various digital systems including drug search (Legemiddelsøk) and regulatory databases but these are internal government systems rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Marketing Authorisation for Medicines
• Clinical Trial Authorisation Review and authorisation of clinical trial applications submitted by sponsors seeking to conduct trials of medicinal products in Norway.
• Pharmacovigilance and Adverse Drug Reaction Monitoring Continuous monitoring of medicine safety after marketing authorisation, including collection and assessment of adverse drug reaction reports from healthcare professionals and the public.
• Medical Device Regulation and Supervision Registration, conformity assessment support, and post-market surveillance of medical devices marketed in Norway.
• Blood, Cell and Tissue Regulation Supervision and inspection of blood banks, cell and tissue establishments to ensure safety and quality standards.

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Irish Health Products Regulatory Authority (HPRA): Ireland's combined medicines and medical device regulator; closely comparable integrated scope to DMP, though operating in a different national market with its own manufacturing-heavy base.
• Austrian Agency for Health and Food Safety (AGES) – Medicines & Medical Devices: Austria's medicines and medical device regulatory unit within AGES; comparable integrated medicines-and-devices mandate and EU regulatory footprint in another smaller EU member state.

Broad incumbents

• Dutch Medicines Evaluation Board (CBG-MEB): Netherlands medicines regulator with comparable mandate and strong EU worksharing involvement; serves as a frequent Reference Member State whose decisions DMP aligns with in MRP/DCP procedures.
• European Medicines Agency (EMA): EU-level regulator whose centralized procedures, scientific guidelines, and Eudamed/CTIS platforms directly shape DMP's day-to-day work; EMA's evolution toward earlier access pathways and HTA coordination constrains and amplifies DMP's role.
• German Federal Institute for Drugs and Medical Devices (BfArM): Germany's federal medicines and device regulator with significantly larger scale; comparable mandate covering marketing authorization, pharmacovigilance, and medical device oversight, and a key reference for EU regulatory practice.
• French National Agency for the Safety of Medicines and Health Products (ANSM): France's national medicines and medical device safety agency; equivalent scope to DMP across authorization, surveillance, and inspections, at much larger absolute scale.
• UK Medicines and Healthcare products Regulatory Agency (MHRA): Post-Brexit UK regulator offering comparable medicines and device oversight plus novel pathways (ILAP); a broader-scale incumbent with similar end-to-end regulatory scope including devices and clinical trials.

Direct peers

• Danish Medicines Agency (Lægemiddelstyrelsen): Denmark's national medicines regulator with overlapping responsibilities in marketing authorization, clinical trials, pharmacovigilance, and medical device oversight, serving a similarly sized Nordic population.
• Swedish Medical Products Agency (Läkemedelsverket): Sweden's national medicines and medical device regulator; structurally the closest analogue to DMP, operating an identical mandate across approvals, pharmacovigilance, HTA-adjacent work, and clinical trial oversight in a neighboring Nordic market.
• Finnish Medicines Agency (Fimea): Finland's medicines regulator operating marketing authorization, pharmacovigilance, and HTA functions; comparable in scope and Nordic regulatory cooperation framework to DMP.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/legemiddelverket
• LinkedInlinkedin.com/company/direktoratetformedisinskeprodukter
• Xx.com/Legemiddelinfo

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Norwegian Medicines Agency